Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
BIOLINERX SP ADR
(NQ:
BLRX
)
1.640
USD
UNCHANGED
Official Closing Price
/ Updated:
3:59 PM EDT, Jun 19, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
1.630
Bid (Size)
1.630 (300)
Ask (Size)
1.650 (200)
Prev. Close
1.640
Today's Range
1.600 - 1.680
52wk Range
1.550 - 5.100
Shares Outstanding
22,255,386
Dividend Yield
N/A
Top News
More News
Week in Review: Mindray Medical Buys US Ultrasound Company for $105 Million
June 15, 2013
Mindray Medical will pay $105 million to acquire Zonare Medical Systems, a California high-end ultrasound device maker; Simcere Pharma announced a third drug development collaboration with...
Read More
from
ChinaBio® Today
Chia-tai Tianqing Pharma Gains China Rights for Hepatitis C Drug from BioLineRx
June 10, 2013
Jiangsu Chia-tai Tianqing Pharmaceutical Co. in-licensed China rights to BL-8030, an oral treatment for hepatitis C virus, from BioLineRx, an Israeli clinical-stage pharma. CTTQ makes chemical drugs...
Read More
from
ChinaBio® Today
More News
Read More
BioLineRx (BLRX), CTTQ Enter BL-8030 Development Collaboration
June 10, 2013
from
StreetInsider.com News Articles
BioLineRx Enters into Collaboration to Develop and Commercialize Hepatitis C Drug with CTTQ, Leading Chinese Pharma Company for Liver Disease Therapeutics
June 10, 2013
from
Business Wire News Releases
BioLineRx (BLRX) Enrolls First Patient in BL-8040 Phase 2
June 06, 2013
from
StreetInsider.com News Articles
BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BL-8040, for Treatment of Leukemia
June 06, 2013
from
Business Wire News Releases
BioLineRx (BLRX) Enters $20M ATM Offering w/ Stifel
May 17, 2013
from
StreetInsider.com News Articles
BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel, Nicolaus & Company
May 17, 2013
from
Business Wire News Releases
BioLineRx to Present at the Oppenheimer 14th Annual Israeli Conference on May 12th
May 09, 2013
from
Business Wire News Releases
BioLineRx Reports First Quarter 2013 Results
May 07, 2013
from
Business Wire News Releases
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here